AZN - AstraZeneca's planned purchase of Alexion approved by U.K. competition regulator

Roland Magnusson/iStock Editorial via Getty Images AstraZeneca's (AZN) planned $39B acquisition of Alexion (ALXN) has been approved by the U.K.'s Competition and Markets Authority ("CMA"), according to the regulator's website. The antitrust regulator began its inquiry in late May. On May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created Last week, AstraZeneca’s acquisition of Alexion cleared in Europe.

For further details see:

AstraZeneca's planned purchase of Alexion approved by U.K. competition regulator